Cargando…
ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth
A significant proportion of breast cancers are driven by ErbB2/Her2 oncoprotein that they overexpress. These malignancies are typically treated with various ErbB2-targeted drugs, but many such cancers develop resistance to these agents and become incurable. Conceivably, treatment of ErbB2-positive c...
Autores principales: | Liu, Xiaoyang, Chipurupalli, Sandhya, Jiang, Peijia, Tavasoli, Mahtab, Yoo, Byong Hoon, McPhee, Michael, Mazinani, Sina, Francia, Giulio, Kerbel, Robert S., Rosen, Kirill V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357009/ https://www.ncbi.nlm.nih.gov/pubmed/35933456 http://dx.doi.org/10.1038/s41419-022-05117-9 |
Ejemplares similares
-
ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth
por: Khan, Iman Aftab, et al.
Publicado: (2018) -
Three-dimensional growth sensitizes breast cancer cells to treatment with ferroptosis-promoting drugs
por: Chipurupalli, Sandhya, et al.
Publicado: (2023) -
Mek activity is required for ErbB2 expression in breast cancer cells detached from the extracellular matrix
por: Khan, Iman A., et al.
Publicado: (2017) -
Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity
por: Durcker, Arik, et al.
Publicado: (2020) -
Correction to: Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity
por: Drucker, Arik, et al.
Publicado: (2020)